Literature DB >> 22869086

New Cell-Based Therapy Paradigm: Induction of Bone Marrow-Derived Multipotent Mesenchymal Stromal Cells into Pro-Inflammatory MSC1 and Anti-inflammatory MSC2 Phenotypes.

Aline M Betancourt1.   

Abstract

Cell-based therapies (CBTs) are quickly taking hold as a revolutionary new approach to treat many human diseases. Among the cells used in these treatments, multipotent mesenchymal stromal cells, also often and imprecisely termed mesenchymal stem cells (MSC), are widely used because they are considered clinically safe, unique in their immune-modulating capabilities, easily obtained from adult tissues, and quickly expanded as well as stored. However, despite these established advantages, there are limiting factors to employing MSCs in these therapeutic strategies. Foremost is the lack of a general consensus on a definition of these cells, marring efforts to prepare homogeneous lots and more importantly complicating their in vitro and in vivo investigation. Furthermore, although one of the most profound clinical effects of MSC intravenous administration is the modulation of host immune responses, no adequate ex vivo assays exist to consistently predict the therapeutic effect of each MSC lot in the treated patient. Until these issues are addressed, this very promising and safe new therapeutic approach cannot be used to its full advantage. However, these confounding issues do present exciting opportunities. The first is an opportunity to discover unknown aspects of host immune responses because the unique effect driven by MSC infusion on a patient's immunity has not yet been identified. In addition, there is an opportunity to develop methods, tests, and tools to better define MSCs and MSC-based therapy and provide consistency in preparation and effect. To this end, my laboratory recently developed a new approach to induce uniform pro-inflammatory MSC1 and anti-inflammatory MSC2 phenotypes from bone marrow-derived MSC preparations. I anticipate that MSC1 and MSC2 provide convenient tools with which to address some of these limitations and will help advance safe and effective CBTs for human disease.

Entities:  

Year:  2013        PMID: 22869086     DOI: 10.1007/10_2012_141

Source DB:  PubMed          Journal:  Adv Biochem Eng Biotechnol        ISSN: 0724-6145            Impact factor:   2.635


  7 in total

1.  Unique characteristics of human mesenchymal stromal/progenitor cells pre-activated in 3-dimensional cultures under different conditions.

Authors:  Joni H Ylostalo; Thomas J Bartosh; April Tiblow; Darwin J Prockop
Journal:  Cytotherapy       Date:  2014-09-16       Impact factor: 5.414

Review 2.  Interactions between MSCs and immune cells: implications for bone healing.

Authors:  Tracy K Kovach; Abhijit S Dighe; Peter I Lobo; Quanjun Cui
Journal:  J Immunol Res       Date:  2015-04-27       Impact factor: 4.818

3.  MSC therapy attenuates obliterative bronchiolitis after murine bone marrow transplant.

Authors:  Kashif Raza; Trevor Larsen; Nath Samaratunga; Andrew P Price; Carolyn Meyer; Amy Matson; Michael J Ehrhardt; Samuel Fogas; Jakub Tolar; Marshall I Hertz; Angela Panoskaltsis-Mortari
Journal:  PLoS One       Date:  2014-10-01       Impact factor: 3.240

4.  Low level laser (LLL) attenuate LPS-induced inflammatory responses in mesenchymal stem cells via the suppression of NF-κB signaling pathway in vitro.

Authors:  Kan Yin; Rongjia Zhu; Shihua Wang; Robert Chunhua Zhao
Journal:  PLoS One       Date:  2017-06-08       Impact factor: 3.240

Review 5.  Age-Related Changes in the Inflammatory Status of Human Mesenchymal Stem Cells: Implications for Cell Therapy.

Authors:  Ying Zhang; Maanasa Ravikumar; Ling Ling; Victor Nurcombe; Simon M Cool
Journal:  Stem Cell Reports       Date:  2021-02-25       Impact factor: 7.765

Review 6.  Therapeutic Mesenchymal Stem/Stromal Cells: Value, Challenges and Optimization.

Authors:  Mehdi Najar; Rahma Melki; Ferial Khalife; Laurence Lagneaux; Fatima Bouhtit; Douaa Moussa Agha; Hassan Fahmi; Philippe Lewalle; Mohammad Fayyad-Kazan; Makram Merimi
Journal:  Front Cell Dev Biol       Date:  2022-01-14

Review 7.  Advances in mesenchymal stromal cell therapy for acute lung injury/acute respiratory distress syndrome.

Authors:  Chang Liu; Kun Xiao; Lixin Xie
Journal:  Front Cell Dev Biol       Date:  2022-08-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.